Search research articles
Contact Us
Filters
Showing results (1-10 of 36) with videos related to
Page
of 4
Sort By:
Revue Medicale Suisse
|
August 25, 2021
[Potential role of sacubitril/valsartan combination in type 2 diabetes]
Nathalie Esser, Nicolas Paquot
Revue Medicale Suisse
|
August 23, 2023
[Update of nutritional recommendations in the treatment of type 2 diabetes]
Nathalie Esser, Nicolas Paquot
Diabetologia
|
May 16, 2019
Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
Nathalie Esser, Sakeneh Zraika
Expert Opinion on Investigational Drugs
|
October 28, 2014
Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease
Nathalie Esser, Nicolas Paquot, André J Scheen
Diabetologia
|
September 7, 2020
Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia
Nathalie Esser, Kristina M Utzschneider, Steven E Kahn
Revue Medicale De Liege
|
March 15, 2024
[Don't neglect metabolic syndrome]
André Scheen, Françoise Luyckx, Nathalie Esser, et al.
Revue Medicale De Liege
|
October 10, 2025
[Semaglutide 2.4 mg (Wegovy®) for the management of clinical obesity with weight-related complications]
André Scheen, Nathalie Esser, Jenny De Flines, et al.
Endocrinology
|
March 25, 2023
Acute Inhibition of Intestinal Neprilysin Enhances Insulin Secretion via GLP-1 Receptor Signaling in Male Mice
Nathalie Esser, Thomas O Mundinger, Breanne M Barrow, et al.
Endocrinology
|
July 2, 2024
Gut-specific Neprilysin Deletion Protects Against Fat-induced Insulin Secretory Dysfunction in Male Mice
Nathalie Esser, Stephen M Mongovin, Breanne M Barrow, et al.
Islets
|
August 25, 2018
Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner
Nathalie Esser, Breanne M Barrow, Edwina Choung, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 36) with videos related to
Sort By:
Page
of 4
Revue Medicale Suisse
|
August 25, 2021
[Potential role of sacubitril/valsartan combination in type 2 diabetes]
Nathalie Esser, Nicolas Paquot
Revue Medicale Suisse
|
August 23, 2023
[Update of nutritional recommendations in the treatment of type 2 diabetes]
Nathalie Esser, Nicolas Paquot
Diabetologia
|
May 16, 2019
Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
Nathalie Esser, Sakeneh Zraika
Expert Opinion on Investigational Drugs
|
October 28, 2014
Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease
Nathalie Esser, Nicolas Paquot, André J Scheen
Diabetologia
|
September 7, 2020
Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia
Nathalie Esser, Kristina M Utzschneider, Steven E Kahn
Revue Medicale De Liege
|
March 15, 2024
[Don't neglect metabolic syndrome]
André Scheen, Françoise Luyckx, Nathalie Esser, et al.
Revue Medicale De Liege
|
October 10, 2025
[Semaglutide 2.4 mg (Wegovy®) for the management of clinical obesity with weight-related complications]
André Scheen, Nathalie Esser, Jenny De Flines, et al.
Endocrinology
|
March 25, 2023
Acute Inhibition of Intestinal Neprilysin Enhances Insulin Secretion via GLP-1 Receptor Signaling in Male Mice
Nathalie Esser, Thomas O Mundinger, Breanne M Barrow, et al.
Endocrinology
|
July 2, 2024
Gut-specific Neprilysin Deletion Protects Against Fat-induced Insulin Secretory Dysfunction in Male Mice
Nathalie Esser, Stephen M Mongovin, Breanne M Barrow, et al.
Islets
|
August 25, 2018
Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner
Nathalie Esser, Breanne M Barrow, Edwina Choung, et al.
Page
of 4